Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The ECRAN-PLASMA study aims to analyze the characteristics of patients with Mycoplasma pneumoniae or Chlamydia pneumoniae pneumonia hospitalized in intensive care units (ICU), continuous monitoring units (USC), or intensive pulmonary care units (USIP). It evaluates their management, prognosis, and macrolide resistance rates.
The ECRAN-PLASMA study focuses on Mycoplasma pneumoniae and Chlamydia pneumoniae infections in intensive care units (ICU), continuous monitoring units (USC), and intensive pulmonary care units (USIP). It aims to better understand the epidemiology, management, and prognosis of these infections, particularly in light of the resurgence of cases following the COVID-19 pandemic and the increasing resistance to macrolides.
Mycoplasmas are bacteria lacking a cell wall, making them resistant to beta-lactam antibiotics. M. pneumoniae adheres to the respiratory epithelium and produces a toxin (CARD-TX) that plays a role in disease pathogenesis. Transmission occurs through aerosols and droplets, with its prevalence likely underestimated due to often mild symptoms. However, in elderly or vulnerable patients, the infection can progress to severe forms requiring intensive care hospitalization, with a significant mortality rate.
The study includes all patients hospitalized in USC, USIP, or ICU who test positive for Mycoplasma pneumoniae or Chlamydia pneumoniae during the inclusion period. Its main objectives are to describe patient characteristics, assess factors associated with disease severity and prognosis, and analyze macrolide resistance.
Expected outcomes include estimating the incidence of Mycoplasma pneumoniae and Chlamydia pneumoniae pneumonia in intensive care settings, gaining a better understanding of at-risk patient profiles, and optimizing patient management. The study also aims to improve prevention strategies and guide future clinical research on these infections.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Infectious disease epidemiology | Other | evaluation of patient management, prognosis, and macrolide resistance rates in severe Mycoplasma pneumoniae and Chlamydia pneumoniae infections. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Severe Mycoplasma pneumoniae and Chlamydia pneumoniae Infections | Number of patients hospitalized in ICU, USC, or USIP with a confirmed diagnosis of Mycoplasma pneumoniae or Chlamydia pneumoniae. | From hospital admission to hospital discharge (up to 60 days) |
| Measure | Description | Time Frame |
|---|---|---|
| In-hospital Mortality Rate | Proportion of patients who died during the index hospitalization among patients with confirmed infection, assessed from medical records. | From hospital admission to hospital discharge (up to 60 days) |
| Length of Stay in ICU and Hospital |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patients hospitalized in Intermediate Care Units (USC), Intensive Respiratory Care Units (USIP), and Intensive Care Units (ICU) who test positive for Mycoplasma pneumoniae or Chlamydia pneumoniae
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medecine intensive-reanimation | Le Kremlin-Bicêtre | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011014 | Pneumonia |
| D007239 | Infections |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Number of days spent in the ICU and total hospitalization duration. |
| From hospital admission to hospital discharge (up to 60 days) |
| Macrolide Resistance Rate | Percentage of patients infected with a macrolide-resistant strain. | At time of microbiological diagnosis (baseline) |
| Need for invasive mechanical ventilation | Proportion of patients requiring invasive mechanical ventilation during hospitalization, assessed from medical records. | From hospital admission to hospital discharge (up to 60 days) |
| Use of respiratory and supportive therapies | Proportion of patients receiving each therapeutic modality (oxygen therapy, non-invasive ventilation, invasive mechanical ventilation, ECMO) during hospitalization, assessed from medical records. | From hospital admission to hospital discharge (up to 60 days) |
| Time from Symptom Onset to ICU Admission | Time elapsed between the onset of symptoms and hospitalization in USC, USIP, or ICU. | At patient admission. |
| In-hospital mortality compared with other bacterial pneumonias | Difference in in-hospital mortality rates between patients with Mycoplasma or Chlamydia pneumoniae infection and patients with other bacterial pneumonias, assessed from medical records. | From hospital admission to hospital discharge (up to 60 days) |
| Vital status at hospital discharge | Proportion of patients alive at hospital discharge, assessed from medical records. | During hospitalization (up to 60 days) |
| Respiratory support at hospital discharge | Proportion of patients requiring respiratory support (oxygen therapy or mechanical ventilation) at hospital discharge, assessed from medical records. | During hospitalization (up to 60 days) |
| Occurrence of acute respiratory distress syndrome (ARDS) | Proportion of patients who developed acute respiratory distress syndrome during hospitalization, assessed from medical records. | From hospital admission to hospital discharge (up to 60 days) |